132 related articles for article (PubMed ID: 8936659)
1. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
Kung AW; Michon J; Tai KS; Chan FL
Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
[TBL] [Abstract][Full Text] [Related]
2. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
[TBL] [Abstract][Full Text] [Related]
5. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
Dickinson AJ; Vaidya B; Miller M; Coulthard A; Perros P; Baister E; Andrews CD; Hesse L; Heverhagen JT; Heufelder AE; Kendall-Taylor P
J Clin Endocrinol Metab; 2004 Dec; 89(12):5910-5. PubMed ID: 15579735
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
Stan MN; Garrity JA; Bradley EA; Woog JJ; Bahn MM; Brennan MD; Bryant SC; Achenbach SJ; Bahn RS
J Clin Endocrinol Metab; 2006 Dec; 91(12):4817-24. PubMed ID: 16984988
[TBL] [Abstract][Full Text] [Related]
9. Urinary glycosaminoglycans in Graves' ophthalmopathy.
Kahaly G; Schuler M; Sewell AC; Bernhard G; Beyer J; Krause U
Clin Endocrinol (Oxf); 1990 Jul; 33(1):35-44. PubMed ID: 2401097
[TBL] [Abstract][Full Text] [Related]
10. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.
Macchia PE; Bagattini M; Lupoli G; Vitale M; Vitale G; Fenzi G
J Endocrinol Invest; 2001 Mar; 24(3):152-8. PubMed ID: 11314743
[TBL] [Abstract][Full Text] [Related]
11. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
12. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.
Prummel MF; Mourits MP; Berghout A; Krenning EP; van der Gaag R; Koornneef L; Wiersinga WM
N Engl J Med; 1989 Nov; 321(20):1353-9. PubMed ID: 2519530
[TBL] [Abstract][Full Text] [Related]
13. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
Ozata M; Bolu E; Sengul A; Tasar M; Beyhan Z; Corakci A; Gundogan MA
Thyroid; 1996 Aug; 6(4):283-8. PubMed ID: 8875747
[TBL] [Abstract][Full Text] [Related]
14. Effect of octreotide treatment on Graves' ophthalmopathy.
Uysal AR; Corapçioğlu D; Tonyukuk VC; Güllü S; Sav H; Kamel N; Erdoğan G
Endocr J; 1999 Aug; 46(4):573-7. PubMed ID: 10580750
[TBL] [Abstract][Full Text] [Related]
15. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy.
Terwee CB; Prummel MF; Gerding MN; Kahaly GJ; Dekker FW; Wiersinga WM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):145-55. PubMed ID: 15670189
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
Metab Pediatr Syst Ophthalmol (1985); 1988; 11(3):133-40. PubMed ID: 3205168
[TBL] [Abstract][Full Text] [Related]
17. Increased retinal blood flow in patients with Graves' disease: influence of thyroid function and ophthalmopathy.
Kurioka Y; Inaba M; Kawagishi T; Emoto M; Kumeda Y; Inoue Y; Morii H; Nishizawa Y
Eur J Endocrinol; 2001 Feb; 144(2):99-107. PubMed ID: 11182745
[TBL] [Abstract][Full Text] [Related]
18. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy].
Pilarska K; Kulig G; Krzystolik Z
Pol Arch Med Wewn; 2001 Feb; 105(2):139-44. PubMed ID: 11505748
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS
J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
